Abstract
Several experimental studies suggest a role of the gut microbiota in the pathophysiology of Parkinson’s disease (PD) via the gut-brain axis. In addition, the gut microbiota can influence the metabolism of levodopa, which is the mainstay of treatment of PD. Therefore, modifying the gut microbiota by fecal microbiota transplantation (FMT) could be a supportive treatment strategy. We developed a study protocol for a single center, prospective, self-controlled, interventional, safety and feasibility donor-FMT pilot study with randomization and double blinded allocation of donor feces. The primary objectives are to assess feasibility and safety of FMT in PD patients. Secondary objectives are to explore whether FMT leads to alterations of motor complications and PD symptoms in the short term, determine alterations in gut microbiota composition and donor-recipient microbiota similarities and their association with PD symptoms and motor complications, assess the ease of the study protocol and examine FMT-related adverse events in PD patients. The study population will consist of 16 idiopathic PD patients that use levodopa and experience motor complications. They will receive FMT with feces from one of two selected healthy human donors. Patients will be pretreated with vancomycin and bowel lavage to increase donor feces engraftment, and domperidone to prevent nausea and regurgitation. The FMT will be performed via direct injection of the fecal suspension into the duodenum via a gastroscope. There will be six follow-up moments during three months. Blood will be drawn on three occasions. Physical examination, filling in of questionnaires and a diary, and collection of stool samples are performed at baseline and each in-person follow-up visit (except for the FMT visit). This study was approved by the Medical Ethical Committee Leiden Den Haag Delft (ref. P20.087) and is registered in the Netherlands Trial Register (NL9438). Study results will be disseminated through publication in peer-reviewed journals and international conferences.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Trial registration number NL9438 (Netherlands Trial Register)
Funding Statement
This study was funded by the Dutch Parkinson patients association (received by M.F. Contarino grant number: 2019-R03 https://www.parkinson-vereniging.nl/?gclid=Cj0KCQiA09eQBhCxARIsAAYRiynsGcALfezVybhdZljKbSgDfrR9rEiIjxuvXqnDYWgG3bJQ62gyqKsaAlbbEALw_wcB). There was an in-kind contribution of CMAT, LUMC, LUMC Biobank Parkinson and the NDFB. The Dutch Parkinson patients association had no role in the data collection and analysis, decision to publish, or preparation of the manuscript. A preliminary version of this study protocol was discussed with two patient-researchers of the Dutch Parkinson patients association, to review the study load, the safety and the patient-centered value of the study. Outside this work, MFC received travel support from Boston Scientific, she was in an Advisory board of Medtronic (fees to institution), she was an independent consultant for research and/or educational issues (fees to institution) for Medtronic, Boston Scientific, Inbrain, and CHDR, she received speaking fees of Abbvie (CME activity) and ECMT (CME activity), she received research support from Medtronic (unrestricted educational grant to institution), Global Kinetics Corporation (research support in-kind) and Abbvie (grant support to institution). EMT and EJK of the NDFB report an unrestricted research grant of Vedanta Biosciences (https://www.vedantabio.com/), which was not specifically granted for this study. Outside this work, JJvH has received grants from the Alkemade-Keuls Foundation, Stichting Parkinson Fonds, Parkinson Vereniging, The Netherlands Organisation for Health Research and Development, Hersenstichting, AbbVie, Michael J Fox Foundation, and research support from the Centre of Human Drug Research. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Leiden-Den Haag-Delft (Medisch-Ethische Toetsingscommissie Leiden Den Haag Delft) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw 16S sequencing data will anonymously be submitted to a public repository (European Nucleotide Archive) when the study is completed.
